A Phase II study comparing the intensification of axitinib in combination with nivolumab versus nivolumab alone following induction therapy with nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma (mRCC) who have not previously achieved a complete response.
Principal Investigator
Dott.ssa Alessandra Mosca
Contact Information for Access
Phase
FASE II
Status
ATTIVO
Objective of the study
To investigate the efficacy of axitinib in patients eligible for standard of care (SOC) following induction therapy with nivolumab plus ipilimumab in patients with mRCC.
ClinicalTrials.gov ID NCT05817903
Sponsor: Oncotech Consortium
Pathologies
Kidney cancer (renal cancer)
Medication
Axitinib in combination with nivolumab or nivolumab alone
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Patients with renal cell carcinoma who have received one or no prior treatments with nivolumab or ipilimumab.
View the full study Back to search page